Subject: Candid Interview with Marley Coffee and PSID Expanded Testing Leads to Massive Market Potential

SCV Client Spotlight
BY READING THIS EMAIL YOU CERTIFY YOU HAVE READ THE DISCLAIMER BELOW AND THE FULL DISCLAIMER PROVIDED THROUGH A LINK AT THE END OF THIS EMAIL. This is a paid advertisement., Inc. is not responsible or held liable for the information in the press releases issued by the companies in these emails. Please always do your own due diligence.
Facebook Twitter YouTube
Candid Interview with Marley Coffee and PSID Expanded Testing Leads to Massive Market Potential
Hot Stock to WatchHot Stock to Watch

Company: Marley Coffee (OTCQB: JAMN)

End of Day:

Price: 0.28

Change (%): - 0.01 (3.45)

Volume: 547,676
JAMN Chart

In a New Audio Interview at, Brent Toevs, CEO, of Marley Coffee, Provides Details Regarding Recently Filed Annual Statement for the Company

AUSTIN, Texas, May 6, 2015 (GLOBE NEWSWIRE) --, Inc. announced today that a new audio interview with Jammin Java Corp. (d/b/a Marley Coffee) (JAMN) ( ("Marley Coffee" "Company"), the sustainably grown, ethically farmed and artisan-roasted gourmet coffee company is now available. The interview can be heard at For a transcript of the interview please visit

Brent Toevs, CEO of Marley Coffee OTC QB: JAMN, called back in to, Inc. to address the company's recently released 10K numbers, their forecasts from the 10K, and what it'll take to reach those goals in an extremely competitive landscape.

Continue Reading

Top PerformerYesterday's Top Performer


End of Day:

Price: 0.23

Change (%): + 0.0299 (14.94)

Volume: 7,603
UVND Chart

U-Vend, Inc. is headquartered in Santa Monica, CA, with additional locations in Stoney Creek, Ontario Canada, Chicago, IL., Los Angeles, CA. and Las Vegas, NV. U-Vend develops, distributes and markets various next-generation, self-serve electronic kiosks in a variety of retail locations in North America. The Company owns and operates self-serve kiosks and merchandisers, and has partnered with numerous national consumer product companies to deliver new and unique customer retail experiences in an automated setting.

Company Information Sheet

SmallCapVoice Clients' News

PositiveID Corporation (OTCQB: PSID)

PositiveID Successfully Expands Testing of Firefly Dx PCR Chip to Food Safety Market, Detecting E. coli in Less Than 20 Minutes

Company Expands Detection Capabilities of Its Prototype Firefly Dx to the Food Safety Testing Market, Which is Projected to Reach 15 Billion Dollars Globally by 2019

DELRAY BEACH, Fla., May 6, 2015 (GLOBE NEWSWIRE) - PositiveID Corporation (“PositiveID” or “Company”) (OTCQB:PSID), a developer of biological detection and diagnostics solutions, today announced that it has successfully detected Escherichia coli (E. coli) bacteria on the PCR (polymerase chain reaction) chip of its Firefly Dx prototype handheld, real-time PCR pathogen detection system, in less than 20 minutes.

E. coli is a common pathogen that can cause diarrhea or other illness outside of the intestinal tract. The types of E. coli that cause diarrhea can be transmitted through contaminated water or food, or through contact with animals or people. These toxin-producing bacteria are called Shiga toxin-producing E. coli (“STEC”). According to the U.S. Centers for Disease Control, an estimated 265,000 STEC infections occur each year in the United States. Some types of STEC can cause severe disease, including bloody diarrhea and hemolytic uremic syndrome, which is a type of kidney failure that can lead to death.

Continue Reading

Other Small Cap News

Company: GenSpera, Inc. (OTCQB: GNSZ)

GenSpera Enters National Phase with Patent Application for Injectable Prodrug Formulations

Company Expands Its Broad Intellectual Property Portfolio

SAN ANTONIO, May 6, 2015 /PRNewswire/ -- GenSpera, Inc. (OTCQB: GNSZ) announced today that the patent application "Injectable Cancer Compositions" has entered the national phase application process in 17 countries and regions, including Europe, Eurasia, Japan, China, Brazil and the United States. When awarded, the resulting patent application will extend the exclusivity period for GenSpera's core intellectual property around its entire platform technology, including its lead drug candidate, mipsagargin, until 2033.

Continue Reading

Company: Bioheart, Inc. (OTCQB: BHRT)

Bioheart Highlights Positive First Quarter Results

"We continue to advance on our plan and pathway to profitability," said Mike Tomas, President and Chief Executive Officer. "Each of our operating divisions: Bioheart, US Stem Cell Training, Vetbiologics and US Stem Cell Clinic have made strategic and tactical gains in the first quarter and we expect to build on our positive momentum as we continue through this year. Physician, patient and veterinarian demand for our products and services continue to expand. To this point, product and service sales growth have emanated from organic, viral communications amongst our network of physicians and patients. To move beyond organic growth to accelerated growth, we are investigating several new marketing initiatives including but not limited to new branding strategies, new pricing strategies, new patient treatment financing options as well as upgrades to our websites and new B-to-B and B-to-C marketing campaigns. We recently announced increases to our staff to facilitate current and future anticipated sales growth. We remain confident in our abilities and steadfast on our objectives and desire to create positive outcomes for our patients and positive investment outcomes for our shareholders."

Continue Reading

Market News

By Richard Leong: Reuters

Global bond rout deepens, oil hits year's high

(Reuters) - A global selloff in government bonds deepened on Wednesday as long-term U.S. and European borrowing costs reached their highest level this year, spreading anxiety into stock and other markets.

The standoff between Greece and its lenders, together with disappointing data on private U.S. jobs growth, kept a lid on the more than a week-long rise in benchmark U.S. and German yields, underpinned by reduced worries about deflation in the euro zone.

"If the rise in yield resulting from dumping Bunds is compounded into other G10 government bonds by possible signs of oil-driven reflation currents, then stocks will have to take notice," said City Index Chief Markets strategist Ashraf Laidi in London.

Continue Reading

By Peter Schacknow:

Early movers: GEVA, MGI, JPM, WEN, NWSA & more

Check out which companies are making headlines before the bell:

Synageva BioPharma - The drug maker will be acquired by Alexion Pharmaceuticals for 8.4 billion dollars in cash and stock, valuing Synageva at $230 per share. That's well above Synageva's Tuesday closing price of $95.87 per share.

MoneyGram International -Sources tell the Financial Times that MoneyGram has hired financial advisors, but the paper also said a Bloomberg report telling of talks with Western Union is not true.

Vitamin Shoppe -The nutritional products retailer fell 11 cents short of estimates with quarterly profit of 63 cents per share, with revenue also below analyst forecasts. The company also cut guidance for the year, saying it was facing a combination of "external headwinds and margin pressure".

Continue Reading

Like Us on FacebookFollow Us on Twitter

SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, publicly available material information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that this information, which originates from third parties, is accurate. We do not have the resources to confirm the accuracy of all information obtained from third parties. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to, Inc. by companies featured on our website or in our e-mail communications.

About Penny Stocks